Testosterone and Bone Health in Men: The Overlooked Connection
Osteoporosis is widely considered a women's disease, but men account for 30% of all hip fractures, and male osteoporosis is dramatically underdiagnosed and undertreated. Testosterone plays a critical role in maintaining bone density in men, and low testosterone is a major, modifiable risk factor for fracture.
When most people think about osteoporosis, they think about women, postmenopausal women losing bone density as estrogen declines. This association is so strong that osteoporosis is often called a "women's disease," and bone density screening guidelines focus primarily on women.
This framing has a serious consequence: male osteoporosis is dramatically underdiagnosed and undertreated, even though men account for approximately 30% of all hip fractures and have significantly higher mortality following hip fracture than women.
Testosterone plays a critical role in maintaining bone density in men, both directly and through its conversion to estradiol. Low testosterone is a major, modifiable risk factor for osteoporosis and fracture in men. Yet most men with low testosterone are never screened for bone loss, and most men with osteoporosis are never evaluated for hypogonadism.
This article explores the relationship between testosterone and bone health, the scope of the problem, and what can be done about it.
How Testosterone Maintains Bone Density
Bone is living tissue that is continuously being broken down and rebuilt through a process called bone remodeling. Two types of cells drive this process:
- Osteoblasts: Bone-building cells that synthesize new bone matrix
- Osteoclasts: Bone-resorbing cells that break down old bone
Bone density is maintained when osteoblast activity equals or exceeds osteoclast activity. When osteoclast activity dominates, as happens with aging, hormone deficiency, and certain medical conditions, bone density declines.
Testosterone influences bone remodeling through multiple mechanisms:
Direct Effects on Bone Cells
Bone cells express androgen receptors. Testosterone directly stimulates osteoblast activity and inhibits osteoclast activity, promoting bone formation and reducing bone resorption. This direct anabolic effect on bone is independent of testosterone's conversion to estradiol.
Conversion to Estradiol
In men, approximately 20% of circulating estradiol is produced directly by the testes; the remaining 80% is produced by peripheral conversion of testosterone to estradiol by the enzyme aromatase, primarily in adipose tissue. Estradiol is actually the dominant sex hormone for bone maintenance in men, it is more potent than testosterone for inhibiting bone resorption.
This means that low testosterone leads to low estradiol, which leads to accelerated bone loss. Men with very low estradiol levels (below approximately 25 pg/mL) have dramatically higher fracture risk regardless of their testosterone levels.
Growth Hormone and IGF-1
Testosterone stimulates growth hormone secretion and increases IGF-1 (insulin-like growth factor 1) levels. IGF-1 is a potent stimulator of osteoblast activity and bone formation. Low testosterone → low IGF-1 → reduced bone formation.
Muscle Mass and Mechanical Loading
Testosterone is the primary driver of muscle mass in men. Muscle contraction applies mechanical stress to bone, which stimulates bone formation (Wolff's Law). Low testosterone → reduced muscle mass → reduced mechanical loading → reduced bone formation. This creates a vicious cycle where low testosterone causes both muscle loss and bone loss simultaneously.
The Scope of Male Osteoporosis
The statistics on male osteoporosis are sobering:
- 10–15% of men over 50 have osteoporosis
- 30–40% of men over 50 have osteopenia (low bone density, the precursor to osteoporosis)
- Men account for 30% of all hip fractures in the United States
- Men have 2–3 times higher mortality following hip fracture than women, approximately 37% of men die within one year of a hip fracture
- Only 20% of men with osteoporosis are diagnosed before their first fracture
- Only 5% of men with osteoporosis receive treatment
The mortality disparity after hip fracture is striking and poorly understood. It likely reflects a combination of factors: men tend to be older and have more medical comorbidities when they fracture, they are less likely to receive appropriate post-fracture care, and the physiological stress of fracture and surgery may be less well-tolerated.
Low Testosterone and Bone Loss: The Evidence
The relationship between testosterone and bone density in men is well-established:
Population studies: Multiple large population studies have found that men with lower testosterone levels have lower bone mineral density and higher fracture risk. The European Male Ageing Study found that men with testosterone below 8 nmol/L (approximately 230 ng/dL) had significantly lower bone density and higher fracture risk.
Hypogonadism studies: Men with hypogonadism (clinically low testosterone) have dramatically higher rates of osteoporosis. Studies of men with Klinefelter syndrome, pituitary disorders, and other causes of hypogonadism consistently show accelerated bone loss.
Androgen deprivation therapy (ADT): Men treated with ADT for prostate cancer, which suppresses testosterone to castrate levels, lose 2–3% of bone density per year and have dramatically increased fracture risk. This is the clearest demonstration of testosterone's importance for bone health in men.
Testosterone replacement studies: Multiple randomized controlled trials have shown that testosterone replacement therapy (TRT) increases bone mineral density in hypogonadal men. A 2017 study published in the New England Journal of Medicine (the Testosterone Trials) found that TRT increased volumetric bone mineral density and bone strength in older men with low testosterone.
Who Is at Risk?
Men at highest risk for testosterone-related bone loss include:
Men with hypogonadism: Any cause of low testosterone, primary hypogonadism (testicular failure), secondary hypogonadism (pituitary/hypothalamic dysfunction), or age-related decline, increases bone loss risk.
Older men: Testosterone declines approximately 1–2% per year after age 30. By age 70, many men have testosterone levels 30–50% below their peak. This age-related decline is a major contributor to the increased fracture risk seen in older men.
Men on androgen deprivation therapy: As noted above, ADT causes rapid, severe bone loss. All men on ADT should be on bone-protective therapy.
Men with chronic illness: Chronic inflammatory conditions (rheumatoid arthritis, IBD, COPD), chronic corticosteroid use, diabetes, and chronic kidney disease all increase bone loss risk and are often associated with low testosterone.
Men with low BMI: Thin men have less mechanical loading on bones and less adipose tissue for estradiol production.
Men with sedentary lifestyles: Physical inactivity reduces mechanical loading on bone and is associated with lower testosterone.
Men with alcohol use disorder: Alcohol directly suppresses testosterone production and impairs bone formation.
Screening: Who Should Be Tested?
Current guidelines for bone density screening in men are less well-defined than for women. The National Osteoporosis Foundation recommends bone density testing (DEXA scan) for:
- All men over 70
- Men aged 50–69 with risk factors (fracture history, low testosterone, chronic corticosteroid use, smoking, alcohol use, low BMI, family history of osteoporosis)
- Men of any age with a fragility fracture (fracture from minimal trauma)
In addition, all men with low testosterone should have bone density testing, regardless of age. This is a gap in current practice: many men are diagnosed with hypogonadism and started on TRT without ever having a baseline DEXA scan.
Testosterone testing should be considered in men with osteoporosis or osteopenia, particularly if other risk factors are present. A morning total testosterone level is the appropriate first test; if low or borderline, free testosterone and LH/FSH should be measured to characterize the type of hypogonadism.
Treatment: Addressing Both Testosterone and Bone Health
Testosterone Replacement Therapy
For men with hypogonadism and low bone density, TRT is a logical intervention that addresses both problems simultaneously. TRT increases bone mineral density, improves muscle mass and strength, and reduces fall risk, all of which contribute to fracture prevention.
TRT is available in several forms:
- Topical gels and creams: Applied daily; convenient and well-tolerated
- Injections: Testosterone cypionate or enanthate, typically every 1–2 weeks; or testosterone undecanoate (Aveed), every 10 weeks
- Pellets: Implanted subcutaneously every 3–6 months; provide stable levels
- Patches: Applied daily; less commonly used due to skin reactions
The choice of formulation depends on patient preference, lifestyle, and clinical factors. At Roth Family Medicine, we work with each patient to find the formulation that best fits their needs.
Bone-Specific Treatments
For men with significant osteoporosis, bone-specific treatments may be needed in addition to TRT:
Bisphosphonates (alendronate, zoledronic acid): Inhibit osteoclast activity and reduce fracture risk. First-line pharmacological treatment for osteoporosis in men.
Denosumab (Prolia): A monoclonal antibody that inhibits osteoclast activity. Particularly useful for men on ADT.
Teriparatide (Forteo): A parathyroid hormone analog that stimulates bone formation. Used for severe osteoporosis or when bisphosphonates are not tolerated.
Calcium and Vitamin D
Adequate calcium and vitamin D are essential for bone health. In Idaho, where sunlight is limited for much of the year, vitamin D deficiency is extremely common. Optimal vitamin D levels (25-OH vitamin D of 50–80 ng/mL) are important for both bone health and testosterone production.
Recommended intakes:
- Calcium: 1,000–1,200 mg/day from food and supplements combined
- Vitamin D: 1,500–2,000 IU/day for most adults; higher doses may be needed to correct deficiency
Exercise
Weight-bearing exercise and resistance training are the most effective non-pharmacological interventions for bone health. They increase bone density, improve muscle mass and strength, and reduce fall risk. Men with low testosterone and bone loss should be engaged in a structured exercise program that includes both weight-bearing aerobic activity and progressive resistance training.
Monitoring
Men on TRT for bone health should be monitored with:
- DEXA scan at baseline and every 1–2 years
- Testosterone levels (total and free) at 3 months after initiation, then every 6–12 months
- Estradiol levels, important because estradiol is the dominant bone-protective hormone
- PSA, prostate-specific antigen, monitored for prostate health
- Hematocrit, TRT can increase red blood cell production
- Bone turnover markers (optional): Can provide earlier feedback on treatment response than DEXA
Bone Health at Roth Family Medicine
At Roth Family Medicine & Mental Health, we take a comprehensive approach to men's health that includes bone health as a core component. We screen for low testosterone, order DEXA scans when appropriate, and develop individualized treatment plans that address both hormone optimization and bone protection.
If you're a man over 50, or a younger man with risk factors, and you haven't had your testosterone levels or bone density checked, now is the time. Call us at (208) 904-4705 to schedule an evaluation.
Kyle Roth, FNP-BC, APRN, MSN, MHA is a board-certified family nurse practitioner specializing in men's health, hormone optimization, and functional medicine at Roth Family Medicine & Mental Health in Pocatello, Idaho.
Explore Topics
Written by
Kyle Roth, FNP-BC, APRN, MSN, MHA
Kyle Roth is a board-certified family nurse practitioner and the founder of Roth Family Medicine & Mental Health in Pocatello, Idaho, where he focuses on treatment-resistant depression, TMS, and ketamine-assisted care, with telehealth across Idaho and Utah.